Nov 18, 2020 20:00 JST

Source: Eisai

Eisai: Jyseleca (Filgotinib) for Rheumatoid Arthritis Launches in Japan

A once-daily, oral, JAK inhibitor for the treatment of rheumatoid arthritis in patients who have had an inadequate response to conventional therapies

TOKYO, Nov 18, 2020 - (JCN Newswire) - Gilead Sciences K.K. and Eisai Co., Ltd. today announced that Jyseleca (filgotinib maleate 200 mg and 100 mg tablets), a new once-daily, oral, JAK (Janus kinase) inhibitor that preferentially inhibits JAK1, will be launched in Japan on November 18 for the treatment of rheumatoid arthritis (RA), with prior regulatory approval by the Japanese Ministry of Health, Labour and Welfare.

Jyseleca is indicated for RA (including prevention of structural joint damage) in patients who have had an inadequate response to conventional therapies. The therapy has received approval in Japan and Europe.

Based on a co-promotion agreement entered into by Gilead and Eisai in December 2019, Gilead will hold the marketing authorization of Jyseleca, while Eisai will be responsible for product distribution of Jyseleca in Japan. The companies will collaborate in product information provision activities in Japan.

"It is estimated that approximately 600,000 to 1 million people1 are living with RA across Japan," said Luc Hermans, MD, President and Representative Director, Gilead Sciences, K.K. "While RA treatment is advancing, many patients still do not experience sufficient disease remission, and many unmet medical needs remain. Gilead and Eisai are committed to delivering the new treatment option Jyseleca and supporting RA patients in Japan."

"Eisai has extensive clinical development and commercialization experience in RA and has established a solid RA franchise in Japan," said Hidenori Yabune, President of Eisai Japan, Senior Vice President, Eisai. "With the launch of Jyseleca, we will make further contributions to meet the diverse needs of RA patients and improve their QOL (quality of life)."

Multiple clinical trials are being conducted to investigate the potential role of filgotinib in a variety of diseases, including the Phase 3 SELECTION program in ulcerative colitis and the Phase 3 DIVERSITY program in Crohn?s disease. The safety and efficacy of filgotinib has not been demonstrated for these uses.

About Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

For more information on Gilead Sciences, please visit the company?s website at Window).

For more information on Gilead Sciences K.K., please visit the company?s website at

Source: Eisai
Sectors: Healthcare & Pharm

Copyright ©2021 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release

Eisai: MHLW Grants Orphan Drug Designation in Japan to Novel FGF Receptor Selective Tyrosine Kinase Inhibitor E7090
February 22 2021 14:40 JST
Eisai Receives Corporate Philanthropy Award for Its Efforts to Realize Human Health Care (hhc) Philosophy
February 22 2021 12:11 JST
LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrated Superior Progression-Free Survival (PFS) and Overall Survival (OS) Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
February 15 2021 10:07 JST
Eisai to Launch Parkinson's Disease Treatment Equfina in South Korea
February 01 2021 08:35 JST
Eisai Listed as a Global 100 Most Sustainable Corporation for the Fifth Time
January 26 2021 10:58 JST
Eisai to Present Abstracts on Lenvatinib at 2021 Gastrointestinal Cancers Symposium
January 12 2021 11:37 JST
Eisai Completes Construction of the 5th Manufacturing Building at Kawashima Industrial Park in Japan
December 18 2020 12:09 JST
LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Demonstrated Statistically Significant Improvement in OS, PFS and ORR
December 17 2020 11:47 JST
Eisai: Biogen Files New Drug Application for Aducanumab in Japan
December 11 2020 09:43 JST
Eisai to Present Abstracts on Oncology Products and Pipeline at 43rd Annual San Antonio Breast Cancer Symposium
December 04 2020 11:17 JST
More Press release >>

Latest Press Release

More Latest Release >>